Abstract Interleukin 1 beta recombinant vaccine for treating pulmonary fibrosis and application thereof The invention discloses an IL-1 beta vaccine for treating pulmonary fibrosis. A recombinant PfTrx-IL-1 beta vaccine established by inserting epitope of IL-1 beta into a PfTrx carrier sequence can successfully stimulate an organism to generate high-potency IL-1 beta resistant neutralizing antibody and can obviously relieve pulmonary fibrosis induced by bleomycin. Immunity of the IL-1 beta vaccine can obviously inhibit mouse pulmonary tissue collagen deposition, the vaccine can lower expression level of TGF-beta 1, CTGF and PDGFB in mouse, and these characteristics are highly conducive to slowing down the process of pulmonary fibrosis. Therefore, the IL-1 beta vaccine is expected to be developed into an effective means for treating pulmonary fibrosis.
|Titolo:||Interleukin 1 beta recombinant vaccine for treating pulmonary fibrosis and application thereof (CN108404125B)|
|Data di pubblicazione:||2019|
|Appare nelle tipologie:||5.1 Brevetto concesso|